Updated MEDVi and GobyMeds pricing
At a 70% price reduction, GLP-1RA is predicted to be cost-effective compared to non-SGLT2i standard-of-care therapies (cost-effectiveness ratio [CER] of $22,700)
According to the SURMOUNT-5 trial published in May 2025, participants on the maximum tolerated dose of Semaglutide (1.7 mg or 2.4 mg) achieved an average weight loss of 13.7% over 72 weeks
At Nuviva, we use only the highest-grade weight loss medications, as quality can vary significantly
The jump from 8 mg to 12 mg, where glucagon receptor engagement becomes more complete, produced measurable additional weight loss in the clinical data
Supporting Mitochondrial Health Mitochondria are the energy powerhouses of our cells, but they are also a significant source of free radicals